The IDH1 and IDH2 mutations are also present in 0.9% of colorectal cancer, associated with the BRAF V600E mutation [146], in 0.5% of non-small cell lung carcinoma (NSCLC), co-existing with KRAS mutations [147] and in melanoma, occurring with NRAS mutations [148]. Here, KRAS is linked to non-small cell lung carcinoma.